5 completed, 2 terminated, 1 unknown. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Terminated 2, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Postmenopausal: new trials by email Literature Review of Postmenopausal trials Research Report on Postmenopausal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women LAE102 SC, Placebo SC, LAE102 IV - Postmenopausal, Healthy Adult Female Participants | Phase 1 | Completed | Laekna Limited | 32 | 2025-04-22 | 2025-11-17 |
| Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients Ribociclib, Trastuzumab, Letrozole - HER2-positive Breast Cancer, Postmenopausal | Phase 1 / Phase 2 | Unknown | Yonsei University | 95 | 2019-06-10 | 2022-05-10 |
| Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis - Estrogen Receptor Positive, HER2/Neu Negative | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 10 | 2017-08-02 | 2022-09-26 |
| Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients Everolimus, Laboratory Biomarker Analysis, Letrozole - Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive | Phase 1 | Completed | M.D. Anderson Cancer Center | 37 | 2014-07-17 | 2020-12-19 |
| Effects of Denosumab on the Pharmacokinetics of Etanercept Etanercept, Denosumab - Postmenopausal, Osteopenia | Phase 1 | Terminated | Amgen | 19 | 2011-03-01 | 2017-06-20 |
| AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations AZD1981 - Healthy, Postmenopausal | Phase 1 | Completed | AstraZeneca | 14 | 2009-06-01 | 2009-07-30 |
| Food Effects on the Relative Bioavailability of Different Dosages of Risedronate risedronate - Postmenopausal, Non-lactating | Phase 1 | Completed | Warner Chilcott | 94 | 2008-07-01 | 2011-10-12 |
| A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785) Romosozumab, Placebo - Postmenopausal, Osteopenia | Phase 1 | Completed | Amgen | 48 | 2007-11-14 | 2023-08-30 |
Breast Neoplasms (3) · Bone Diseases, Metabolic (2) · Arthritis (1) · Arthritis, Rheumatoid (1) · Osteoporosis (1)
Skin and Connective Tissue Diseases (4) · Breast Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Skin Diseases (3) · Bone Diseases (2) · Metabolic Diseases (2) · Musculoskeletal Diseases (2) · Nutritional and Metabolic Diseases (2) · Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Immune System Diseases (1) · Joint Diseases (1) · Rheumatic Diseases (1)
Letrozole (3) · Trastuzumab (2) · AZD1981 (1) · Denosumab (1) · Etanercept (1) · Everolimus (1) · Ogivri (1) · PF-05280014 (1) · Risedronic Acid (1) · copanlisib (1) · palbociclib (1) · ribociclib (1) · romosozumab (1) · trastuzumab biosimilar HLX02 (1)
Amgen (2) · AstraZeneca (1) · Jonsson Comprehensive Cancer Center (1) · Laekna Limited (1) · M.D. Anderson Cancer Center (1) · Warner Chilcott (1) · Yonsei University (1)
United States (5) · South Korea (1) · Sweden (1)
Dr. Hugh Coleman, MD (1) · Elisabeth Eden (1) · Eva Pettersson (1) · Filip Janku (1) · Sara Hurvitz (1)
P30CA016672 (1)